Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT03213626 · TERMINATED
Trial details
- NCT number
- NCT03213626
- Sponsor
- Patrick Joseph Loehrer Sr.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-13
- Primary completion
- 2019-04-15
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.